Diabetes as a determinant of mortality in cystic fibrosis

Diabetes Care

Volumn 33, Issue 2, 2010, Pages 311-316

  Chamnan, Parinya ^a   Shine, Brian S F ^b   Haworth, Charles S ^c   Bilton, Diana ^d   Adler, Amanda I ^a,c,e  

^a INSTITUTE OF METABOLIC SCIENCE   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c PAPWORTH HOSPITAL   (United Kingdom)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

^e ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; INSULIN; ORAL ANTIDIABETIC AGENT; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; ASPERGILLOMA; ASPERGILLUS FUMIGATUS; BACTERIUM CULTURE; BODY MASS; BURKHOLDERIA CEPACIA; BURKHOLDERIA CEPACIA INFECTION; CHILD; COHORT ANALYSIS; CORTICOSTEROID THERAPY; CYSTIC FIBROSIS; DIABETES MELLITUS; DIETARY INTAKE; ETHNICITY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FUNGUS CULTURE; GROUPS BY AGE; HAEMOPHILUS INFLUENZAE; HUMAN; INFANT; INSULIN TREATMENT; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FUNCTION TEST; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; NEWBORN; NEWBORN SCREENING; ORAL GLUCOSE TOLERANCE TEST; ORGAN TRANSPLANTATION; PANCREAS INSUFFICIENCY; POISSON DISTRIBUTION; PREDICTOR VARIABLE; PSEUDOMONAS AERUGINOSA; REGISTER; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SPUTUM ANALYSIS; STANDARDIZED MORTALITY RATIO; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; THROAT CULTURE; UNITED KINGDOM;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYSTIC FIBROSIS; DIABETES COMPLICATIONS; FEMALE; GENES, RECESSIVE; GREAT BRITAIN; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 75149147257     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-1215     Document Type: Article

References (25)

1. Cystic Fibrosis Foundation Patient Registry 2007 Annual Data Report, Bethesda, MD
2. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 2007; 29:522-526
3. Bellis G, Cazes MH, Parant A, Gaimard M, Travers C, Le Roux E, Ravilly S, Rault G. Cystic fibrosis mortality trends in France. J Cyst Fibros 2007;6:179-186
4. Dodge JA, Morison S, Lewis PA, Coles EC, Geddes D, Russell G, Littlewood JM, Scott MT. Incidence, population, and survival of cystic fibrosis in the UK, 1968 -95. UK Cystic Fibrosis Survey Management Committee. Arch Dis Child 1997;77:493-496
5. Adler AI, Shine BS, Chamnan P, Haworth CS, Bilton D. Genetic determinants and epidemiology of cystic fibrosis-related diabetes: results from a British cohort of children and adults. Diabetes Care 2008; 31:1789-1794
6. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153:345-352
7. Mehta G, Sims E, Culross F, McCormick J, Mehta A. Potential benefits of the UK Cystic Fibrosis Database. J R Soc Med 2004;97:60-71
8. Pan H, Cole T. Users Guide to lmsGrowth. London, Medical Research Council UK, 2007
9. Rowntree RK, Harris A. The phenotypic consequences of CFTR mutations. Ann Intern Med 2003;67:471-485
10. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. CFTR genotype as a predictor of prognosis in cystic fibrosis. Chest 2006;130:1441-1447
11. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, H?bbs JR, Marshall BC. Spirometric reference values from a sample of the U.S. population. Am J Respir Crit Care Med 1999;159:179-187
12. Office for National Statistics. Mortality Statistics: General. DH1 - Annual Review of the Registrar General on Deaths in England and Wales. Newport, South Wales, Office for National Statistics, 2005
13. Rockhill B, Newman B, Weinberg C. Use and misuse of population attributable fractions. Am J Public Health 1998;88: 15-19
14. Rowe AK, Powell KE, Flanders WD. Why population attributable fractions can sum to more than one. Am J Prev Med 2004; 26:243-249
15. Koch C, Rainisio M, Madessani U, Harms HK, Hodson ME, Mastella G, McKenzie SG, Navarro J, Strandvik B, Investigators of the European Epidemiologic Registry of Cystic Fibrosis. Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol 2001;32:343-350
16. Rosenfeld M, Davis R, FitzSimmons S, Pepe M, Ramsey B. Gender gap in cystic fibrosis mortality. Am J Epidemiol 1997; 145:794-803
17. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis related diabetes: current trends in prevalence, incidence and mortality. Diabetes Care 2009;32:1626-1631
18. McKone EF, Emerson SS, Edwards KL, Aitken ML. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet 2003; 361:1671-1676
19. Bismuth E, Laborde K, Taupin P, Velho G, Ribault V, Jennane F, Grasset E, Sermet I, de Blic J, Lenoir G, Robert JJ. Glucose tolerance and insulin secretion, morbidity, and death in patients with cystic fibrosis. J Pediatr 2008;152:540-545
20. Harvey JN, Craney L, Kelly D. Estimation of the prevalence of diagnosed diabetes from primary and secondary care source data: analysis comparison of record linkage with capture-recapture. J Epidemiol Community Health 2002;56:18-23
21. Onady G, Stolfi A. Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database Syst Rev 2005;3: CD004730
22. Moran A, Pekow P, Grover P, Zorn M, Slovis B, Pilewski J, Tullis E, Liou TG, Allen H. Insulin therapy to improve BMI in cystic fibrosis related diabetes without fasting hyperglycemia: results of the CFRDT Trial. Diabetes Care 2009;32: 1783-1788
23. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
24. Näntö-Salonen K, Kupila A, Simell S, Siljander H, Salonsaari T, Hekkala A, Korhonen S, Erkkola R, Sipilä JI, Haavisto L, Siltala M, Tuominen J, Hakalax J, Hyöty H, Ilonen J, Veijola R, Simell T, Knip M, Simell O. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008;372: 1746-1755
25. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346:1685-1691